61results about "Tachykinin ingredients" patented technology

Disclosed are a method and a corresponding pharmaceutical composition for treating damaged ligaments. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of ligaments damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).

The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury.

The invention is directed to a method of identifying a compound that modulates SP-induced paraptosis by (a) contacting a population of cells with an effective amount of substance P to induce SP-induced paraptosis; (b) contacting a first sub-population of the cells with a test-compound, and a second sub-population of the cells with a control-compound; and (c) comparing the amount of cell death between the first and second sub-populations of cells, where a difference in the amount of cell death between the first and second sub-populations of cells indicates that the test-compound is a compound that modulates SP-induced paraptosis. The invention is also directed to a method of treating a condition associated with excessive cell accumulation by administering to a subject in need of such treatment an effective amount of a compound identified from the method described above where the effective amount of the compound increases SP-induced paraptosis. The invention is further directed to a method of treating a condition associated with excessive cell death by administering to a subject in need of such treatment an effective amount of a compound identified from the method described above where the effective amount of the compound decreases SP-induced paraptosis.

The present invention relates to a hydrogel type cell delivery vehicle composition for wound healing and to a preparation method thereof. More particularly, the present invention relates to a hydrogel type cell delivery vehicle composition in which non-ionic surfactants, growth factors or substance-P, human-derived cells, and the like are distributed in aqueous media, to a use thereof for wound healing, and to a preparation method thereof. The hydrogel type composition of the present invention appropriately delivers cells and / or substance-P to the wound part, and has moistening effects, effects of preventing contraction of the wound, and effects of protecting cells, and can be used in an easy and convenient manner. The cells in the composition are delivered to the wound part to effectively heal the wound when the composition of the present invention is applied to or injected into the wounded body part.

The present invention relates generally to methods for reducing intracranial pressure in a subject. More particularly, the methods of the present invention include administering to the subject an effective amount of a substance P receptor antagonist.

Healing of wounds in mammalian tissue may be enhanced by the application of certain neuropeptides, optionally in combination with known growth promoting hormones. Exemplary neuropeptides include tachykinins, such as Substance P, Substance K, and the like, as well as calcitonin gene-related peptides. The compositions may further include a polymeric delivery carrier and are utilized by applying to the site of the wound. Wounds may be vascular or avascular wounds. The compositions promote elaboration of cellular matrices and development of cellular attachment mechanisms in addition to stimulating cellular proliferation.

The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.

The present invention pertains to biodegradable polymers comprising a non-polymerizable lactone, biodegradable compositions comprising the polymer and a therapeutic agent, the use of the compositions for the sustained release of therapeutic agents, wherein the therapeutic agent is reversibly immobilized on the polymer matrix using ionic complexation between the latent carboxylic groups present on the lactone bearing polymer matrix and a cationic group on the therapeutic agent.

Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin.